Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Premier journal of science.Open Access

Triple-Negative Breast Cancer: Molecular Subtypes, Therapeutic Challenges, and Emerging Strategies—A Systematic Review

View Full Paper
Ask AI
Bookmark
Share

Authors

AVAmi VyasSDSumeet DwivediSKSweta S Koka

Discussion

Loading...

Member takes

Overview

Systematic review analyzes triple-negative breast cancer subtypes and therapeutic challenges, highlighting emerging strategies.

Key Points

  • Triple-negative breast cancer is an aggressive subtype representing 15-20% of breast cancers, with poor prognosis.
  • Diverse molecular subtypes, such as basal-like and luminal androgen receptor, exhibit distinct therapeutic responses based on their profiles.
  • Current therapies include chemotherapy and emerging options like PARP inhibitors and immune checkpoint blockers for personalized treatment.
  • Molecular profiling and biomarker-driven strategies may enable better-targeted approaches in treating triple-negative breast cancer.

Cite This Study

Vyas et al. (2025) studied this question.

synapsesocial.com/papers/68d4232f713b0b5dfea6b5b2https://doi.org/10.70389/pjs.100101
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment2020 · 240 citations